Wintermute Biomedical Inc is a cutting-edge biotechnology company based in Missoula, MT, dedicated to developing safe and effective next-generation therapies for infectious diseases. Leveraging their patented platform, they harness the antimicrobial power of fatty acids by solubilizing them in water using amino acids, allowing for a multitude of applications in healthcare.
Their main focus is on developing Solexan, an undecylenic acid-based formulation, as a topical treatment for shingles. With an established safety profile, Wintermute Biomedical is fast-tracking Solexan into efficacy trials and preparing for a Phase I trial to validate its safety in shingles patients. Additionally, they are actively working on novel treatments for antibiotic-resistant diseases, such as Impetigo, to combat drug-resistant bacteria and improve health outcomes for individuals and society at large.
Generated from the website